Ironwood Pharma (IRWD) Misses Q2 EPS by 6c, Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update
August 3, 2017 4:01 PM EDTLINZESS® (linaclotide) expanded IBS-C/CIC branded prescription market leadership in 2Q 2017 with 19% growth in volume year-over-year and $168 million in U.S. net sales
Positive IW-3718 Phase IIb top-line data in uncontrolled GERD support advancement into Phase III
Multiple additional catalysts expected in 2H 2017, including DUZALLO® (lesinurad and allopurinol) approval and launch, three mid-stage data readouts and four mid- to late-stage trial initiations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
